Based on its overall pharmacological, tissue distribution, and preliminary safety profiles, ZLY28 has advanced to preclinical study as the first‐in‐class intestinal restricted FXR/FABP1 dual modulator for the treatment of NASH/NAFLD. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.